The invention provides relatively short immunogenic peptides, and biologically active variants thereof, associated with leukemia which elicit an immune response. Nucleic acids encoding the immunogenic peptides and antibodies specific for the peptides are also provided. The immunogenic peptides can b
The invention provides relatively short immunogenic peptides, and biologically active variants thereof, associated with leukemia which elicit an immune response. Nucleic acids encoding the immunogenic peptides and antibodies specific for the peptides are also provided. The immunogenic peptides can be included in pharmaceutical compositions, such as cancer vaccines, and used for the treatment of cancer.
대표청구항▼
1. An isolated antigen presenting cell produced in vitro by contacting the antigen presenting cell with an isolated antigen comprising a fragment of CD33 (SEQ ID NO: 4) wherein the fragment comprises the amino acid sequence YLALCLCLI (SEQ ID NO: 1), AIISGDSPV (SEQ ID NO: 2), YIISGDSPV (SEQ ID NO: 3)
1. An isolated antigen presenting cell produced in vitro by contacting the antigen presenting cell with an isolated antigen comprising a fragment of CD33 (SEQ ID NO: 4) wherein the fragment comprises the amino acid sequence YLALCLCLI (SEQ ID NO: 1), AIISGDSPV (SEQ ID NO: 2), YIISGDSPV (SEQ ID NO: 3), YIISGISPV (SEQ ID NO: 6), YLISGDSPV (SEQ ID NO: 7), ALLALCLCL (SEQ ID NO: 8), TIQLNVTYV (SEQ ID NO: 9), YIGSGDSPV (SEQ ID NO: 10), YIIIGDSPV (SEQ ID NO: 11), YIILGDSPV (SEQ ID NO: 12), YIISGDLPV (SEQ ID NO: 13), YIISGDSWV (SEQ ID NO: 14), YIISGDSPL (SEQ ID NO: 15), ALISGDSPV (SEQ ID NO: 16) or LLALCLCLI (SEQ ID NO:42), wherein the fragment is 9-30 amino acids in length. 2. An isolated antigen presenting cell produced in vitro by contacting the antigen presenting cell with an isolated antigen consisting of the amino acid sequence YLALCLCLI (SEQ ID NO: 1), AIISGDSPV (SEQ ID NO: 2), YIISGDSPV (SEQ ID NO: 3), YIISGISPV (SEQ ID NO: 6), YLISGDSPV (SEQ ID NO: 7), ALLALCLCL (SEQ ID NO: 8), TIQLNVTYV (SEQ ID NO: 9), YIGSGDSPV (SEQ ID NO: 10), YIIIGDSPV (SEQ ID NO: 11), YIILGDSPV (SEQ ID NO: 12), YIISGDLPV (SEQ ID NO: 13), YIISGDSWV (SEQ ID NO: 14), YIISGDSPL (SEQ ID NO: 15), ALISGDSPV (SEQ ID NO: 16) or LLALCLCLI (SEQ ID NO: 42). 3. The antigen presenting cell of claim 2, wherein the antigen presenting cell is a dendritic cell or a T2 cell. 4. The antigen presenting cell of claim 2, wherein the antigen presenting cell is a dendritic cell or a T2 cell. 5. A method of treating leukemia in a subject in need thereof, the method comprising administering to the subject a pharmaceutically acceptable preparation of (a) an isolated antigen presenting cell produced in vitro by contacting the antigen presenting cell with an isolated antigen comprising a fragment of CD33 (SEQ ID NO: 4) wherein the fragment comprises the amino acid sequence YLALCLCLI (SEQ ID NO: 1), AIISGDSPV (SEQ ID NO: 2), YIISGDSPV (SEQ ID NO: 3), YIISGISPV (SEQ ID NO: 6), YLISGDSPV (SEQ ID NO: 7), ALLALCLCL (SEQ ID NO: 8), TIQLNVTYV (SEQ ID NO: 9), YIGSGDSPV (SEQ ID NO: 10), YIIIGDSPV (SEQ ID NO: 11), YIILGDSPV (SEQ ID NO: 12), YIISGDLPV (SEQ ID NO: 13), YIISGDSWV (SEQ ID NO: 14), YIISGDSPL (SEQ ID NO: 15), ALISGDSPV (SEQ ID NO: 16) or LLALCLCLI (SEQ ID NO:42), wherein the fragment is 9-30 amino acids in length, or(b) an isolated antigen presenting cell produced in vitro by contacting the antigen presenting cell with an isolated antigen consisting of the amino acid sequence YLALCLCLI (SEQ ID NO: 1), AIISGDSPV (SEQ ID NO: 2), YIISGDSPV (SEQ ID NO: 3), YIISGISPV (SEQ ID NO: 6), YLISGDSPV (SEQ ID NO: 7), ALLALCLCL (SEQ ID NO: 8), TIQLNVTYV (SEQ ID NO: 9), YIGSGDSPV (SEQ ID NO: 10), YIIIGDSPV (SEQ ID NO: 11), YIILGDSPV (SEQ ID NO: 12), YIISGDLPV (SEQ ID NO: 13), YIISGDSWV (SEQ ID NO: 14), YIISGDSPL (SEQ ID NO: 15), ALISGDSPV (SEQ ID NO: 16) or LLALCLCLI (SEQ ID NO: 42). 6. The method of claim 5, wherein the antigen presenting cell is a dendritic cell or a T2 cell. 7. The method of claim 5, wherein the administration of the pharmaceutically acceptable preparation is by an intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal route. 8. The method of claim 5, wherein the pharmaceutically acceptable preparation is administered in an initial dose followed by one or more booster doses. 9. The method of claim 5, comprising a course of chemotherapy. 10. The method of claim 9, wherein the course of chemotherapy comprises the administration of a chemotherapeutic agent selected from the group consisting of 5-FU and cisplatin.
Srivastava Pramod K., Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of neoplastic diseases.
Suni Jukka (Helsinki FIX) Vaheri Antti (Helsinki FIX), Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhanced transmembrane transport of exogenous molecules.
Kikuchi Kokichi,JPX ; Sato Noriyuki,JPX ; Sahara Hiromitsu,JPX ; Yasojima Takahiro,JPX ; Wada Yoshimasa,JPX ; Suzuki Manabu,JPX ; Hamuro Junji,JPX, Peptide capable of inducing immune response to human gastric cancer and agent for preventing or treating human gastric c.
Gould Michael N. (Madison WI) Crowell Pamela L. (Indianapolis IN) Elson Charles E. (Madison WI) Clark Steven S. (Madison WI), Regression of mammalian leukemia cell tumors.
Elliott Robert L. (17310 Masters Pointe Ct. Baton Rouge LA 70810) Head Jonathan F. (6144 Hagerstown Dr. Baton Rouge LA 70817), Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colon.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.